Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02568449 · OUTCOME

Overall Survival

Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent · Source last updated 2021-12-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
Up to 1 year

What was measured

Overall survival will be estimated using standard Kaplan-Meier methods for censored data, from which the median and other statistics of interest will be calculated (e.g., rates at 3 months, 6 months, 12 months).

Groups in this outcome

Treatment (Nintedanib)

Patients receive nintedanib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Nintedanib: Given PO

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Nintedanib)20

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment (Nintedanib)4.1Not reported2.58.7Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        2.5
        upper Limit
        8.7
        value
        4.1
denoms
  1. counts
    1. group Id
      OG000
      value
      20
    units
    Participants
description
Overall survival will be estimated using standard Kaplan-Meier methods for censored data, from which the median and other statistics of interest will be calculated (e.g., rates at 3 months, 6 months, 12 months).
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients receive nintedanib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Nintedanib: Given PO
    id
    OG000
    title
    Treatment (Nintedanib)
param Type
MEDIAN
reporting Status
POSTED
time Frame
Up to 1 year
title
Overall Survival
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice